tert-butyl (1-formylcyclohexyl)carbamate | 594872-65-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (1-formylcyclohexyl)carbamate
• 英文别名: 1-(Boc)amino-1-formylcyclohexane；tert-butyl N-(1-formylcyclohexyl)carbamate
• CAS: 594872-65-8
• 化学式: C₁₂H₂₁NO₃
• 分子量: 227.304
• InChiKey: ZIKUKJDGNXNBEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (1-formylcyclohexyl)carbamate 在 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 [1-(3,5-Dimethyl-benzoyl)-cyclohexyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Optimization of α-acylaminoketone ecdysone agonists for control of gene expression

  摘要：

  Fifteen new alpha-acylaminoketones were prepared by four different routes in an initial effort to optimize the potency of these compounds as ecdysone agonists. The compounds were assayed in mammalian cells expressing the ecdysone receptors from Bombyx mori (BmEcR) and Choristoneura fumiferana (CfEcR) for their ability to cause expression of a reporter gene downstream of an ecdysone response element. A new alpha-acylaminoketone was identified which had activity equal to that of the standard diben-zoylhydrazine ecdysone agonist GS(TM)-E in the assay based on CfEcR. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00315-9
• 作为产物：
  描述：

  1-(N-叔丁氧羰基氨基)环己烷甲酸 在 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 14.83h， 生成 tert-butyl (1-formylcyclohexyl)carbamate
  参考文献：
  名称：

  二氢嘧啶-4-酮往的β-制备的铜（I） -催化的合成和β 3 -氨基酸类似物

  摘要：

  已经成功地开发了铜（I）催化炔酮胺中间体从炔丙基酰胺合成取代的二氢嘧啶-4-酮。合成得到良好的分离产率（80-95％）。室温下温和的反应条件可使反应在数小时内完成，而无需改变立体化学。另外，通过涉及多种反应性亲核试剂，将得到的被取代的二氢嘧啶-4-酮被优雅转化成相应的β-和β 3 -氨基酸的类似物。

  DOI：

  10.1021/jo402670d

文献信息

• [EN] CARBOCYCLIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE PROLINAMIDE CARBOCYCLIQUES
  申请人：INCEPTION 4 INC

  公开号：WO2017222914A1

  公开（公告）日：2017-12-28

  This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新型的Formula (I)的碳环脯氨酰胺衍生物，以及在预防（例如，延缓或降低发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）和相关疾病方面有用的药用盐、溶剂化合物、盐的溶剂化合物和前药。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜脉络膜病变以及视网膜或光感受器细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜脉络膜病变以及视网膜或光感受器细胞的方法，包括：给予所述发明的化合物的治疗有效量。本发明的化合物是HTRA1的抑制剂。因此，本发明的化合物在预防和治疗通过HTRA1（全部或部分）介导的广泛疾病方面有用。本发明的化合物还可用于抑制眼睛或关节炎或相关疾病部位的HTRA1蛋白酶活性。
• Morpholine containing amino acid derivatives
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US04711958A1

  公开（公告）日：1987-12-08

  Amino acid derivatives represented by formula ##STR1## wherein His represents an L-histidyl group, X represents a straight or branched alkoxy group having 1 to 7 carbon atoms, a straight or branched alkylamino group having 1 to 7 carbon atoms, a cycloalkyloxy group having 3 to 7 carbon atoms, a morpholino group, said alkoxy group having one or more halogen atoms as substituents; or a pharmaceutically acceptable salt, are useful in the treatment of hypertension.

  公式##STR1##所代表的氨基酸衍生物，其中His代表L-组氨酸基团，X代表具有1至7个碳原子的直链或支链烷氧基团，具有1至7个碳原子的直链或支链烷基氨基基团，具有3至7个碳原子的环烷氧基团，吗啡啉基团，所述烷氧基团具有一个或多个卤素原子作为取代基；或其药学上可接受的盐，在治疗高血压方面是有用的。
• Structure-based virtual screening for insect ecdysone receptor ligands using MM/PBSA
  作者：Shinri Horoiwa、Taiyo Yokoi、Satoru Masumoto、Saki Minami、Chiharu Ishizuka、Hidetoshi Kishikawa、Shunsuke Ozaki、Shigeki Kitsuda、Yoshiaki Nakagawa、Hisashi Miyagawa

  DOI：10.1016/j.bmc.2019.02.011

  日期：2019.3

  20-hydroxyecdysone. Because synthetic EcR ligands disrupt the normal growth of insects, they are attractive candidates for new insecticides. In this study, the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method was used to predict the binding activity of EcR ligands. Validity analyses using 40 known EcR ligands showed that the binding activity was satisfactorily predicted when the ligand conformational

  蜕皮激素受体（EcR）是一种昆虫蜕皮受体，被蜕皮激素20-羟基蜕皮激素激活。由于合成的EcR配体破坏了昆虫的正常生长，因此它们是新型杀虫剂的诱人候选物。在这项研究中，使用分子力学/泊松玻尔兹曼表面积（MM / PBSA）方法来预测EcR配体的结合活性。使用40种已知EcR配体的有效性分析表明，当引入配体构象自由能术语时，可以令人满意地预测结合活性。随后，将此MM / PBSA方法应用于基于结构的分层虚拟筛选，并从380万种化合物的数据库中选择了12种候选化合物。这些化合物中的五个在基于细胞的竞争性结合测定中具有活性。
• Process Development of CuI/ABNO/NMI-Catalyzed Aerobic Alcohol Oxidation
  作者：Janelle E. Steves、Yuliya Preger、Joseph R. Martinelli、Christopher J. Welch、Thatcher W. Root、Joel M. Hawkins、Shannon S. Stahl

  DOI：10.1021/acs.oprd.5b00179

  日期：2015.11.20

  [Cu(MeCN)4]OTf with a lower-cost Cu source, CuI, reduction of the ABNO loading to 0.05–0.3 mol%, and use of NMI as the only ligand/additive (i.e., without a need for MeObpy). Use of a high flash point solvent, N-methylpyrrolidone, enables safe operation in batch reactions with air as the oxidant. For continuous-flow applications compatible with elevated gas pressures, better performance is observed with acetonitrile

  已经开发出一种用于需氧醇氧化的改进的Cu /硝基甲苯催化剂体系，用于将官能化的伯醇和仲醇氧化为醛和酮，适用于分批和流水工艺。该催化剂已在> 50 g的批量反应中得到证明，解决了与先前报道的（MeO bpy）Cu I / ABNO / NMI催化剂体系（MeO bpy = 4,4'-dimethoxy- 2,2′-联吡啶，ABNO ＝ 9-氮杂双环[3.3.1]壬烷N-氧基，NMI ＝N-甲基咪唑）。重要的催化剂改性方法包括更换[Cu（MeCN）4] OTf具有低成本的铜源CuI，将ABNO的负载量降低至0.05-0.3 mol％，并且使用NMI作为唯一的配体/添加剂（即无需MeO bpy）。使用高闪点溶剂N-甲基吡咯烷酮可在以空气为氧化剂的间歇反应中安全操作。对于与升高的气压兼容的连续流应用，使用乙腈作为溶剂可观察到更好的性能。
• Impact of substituent effects on the design of β-sheet mimetics and β-double helices from (<i>E</i>)-vinylogous γ-amino acid oligomers
  作者：Kuruva Veeresh、Manjeet Singh、Hosahudya N. Gopi

  DOI：10.1039/c9ob01801h

  日期：——

  impact of the substituents and structural differences of two structurally important motifs, β-sheets and β-double helices. Though β-sheets are common structural motifs in protein structures, β-double helices are not common in proteins and peptides. We found that both β-sheet mimetics and β-double helices can be constructed from the homooligomers of α,β-unsaturated γ-amino acids. Results suggested that introducing

  在这里我们报告设计，单晶构象，取代基的影响和两个结构上重要的主题，β-片和β-双螺旋的结构差异。尽管β-折叠是蛋白质结构中常见的结构基序，但β-双螺旋在蛋白质和肽中并不常见。我们发现，β-折叠模拟物和β-双螺旋都可以由α，β-不饱和γ-氨基酸的均聚物构成。结果表明，在α，β-不饱和γ-氨基酸的均聚物的γ-碳上引入gem-dialk取代会导致β-双螺旋构象，而在γ-碳上具有单取代的相同寡聚物显示出β-片状结构。